U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2006
190
Substance Class Protein
Created
by admin
on Mon Mar 31 20:30:35 GMT 2025
Edited
by admin
on Mon Mar 31 20:30:35 GMT 2025
Protein Type FAB
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
ZL1R02VT79
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
FAB-12 VARIANT Y0317
Preferred Name English
RANIBIZUMAB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
RHUFAB
Code English
SUSVIMO
Brand Name English
RG-3645
Code English
immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 1-chain), disulfide with human-mouse monoclonal rhuFAB V2 light chain
Common Name English
ranibizumab [INN]
Common Name English
RANIBIZUMAB [MART.]
Common Name English
RANIBIZUMAB [VANDF]
Common Name English
Ranibizumab [WHO-DD]
Common Name English
RANIBIZUMAB [MI]
Common Name English
RANIBIZUMAB [EMA EPAR]
Common Name English
RBZ
Common Name English
RANIBIZUMAB [USAN]
Common Name English
RANIBIZUMAB [PURPLE BOOK CDER]
Common Name English
RANIBIZUMAB [JAN]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS LUCENTIS (AUTHORIZED: WET MACULAR DEGENERATION)
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
WHO-ATC S01LA04
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
NDF-RT N0000020007
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
NDF-RT N0000178291
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
EMA ASSESSMENT REPORTS LUCENTIS (AUTHORIZED: MYOPIA, DEGENERATIVE)
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
EMA ASSESSMENT REPORTS LUCENTIS (AUTHORIZED: MACULAR EDEMA)
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
WHO-VATC QS01LA04
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
NDF-RT N0000193543
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
NCI_THESAURUS C2496
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
NDF-RT N0000178292
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
Code System Code Type Description
INN
8313
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
DRUG BANK
DB01270
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
WIKIPEDIA
RANIBIZUMAB
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
NCI_THESAURUS
C67562
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
EVMPD
SUB22314
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
MERCK INDEX
m9496
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY Merck Index
DRUG CENTRAL
4971
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
SMS_ID
100000088053
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
RXCUI
595060
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY RxNorm
CAS
347396-82-1
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
FDA UNII
ZL1R02VT79
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
DAILYMED
ZL1R02VT79
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
LACTMED
Ranibizumab
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
MESH
C497368
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
IUPHAR
6779
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
USAN
OO-14
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201825
Created by admin on Mon Mar 31 20:30:35 GMT 2025 , Edited by admin on Mon Mar 31 20:30:35 GMT 2025
PRIMARY
From To
1_22 1_96
1_150 1_206
1_226 2_214
2_23 2_88
2_134 2_194
Related Record Type Details
PF-582
SUB_CONCEPT->SUBSTANCE
RANIBIZUMAB-NUNA
BIOSIMILAR -> PARENT
HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR A
TARGET -> INHIBITOR
RANIBIZUMAB-NUNA
SUB_CONCEPT->SUBSTANCE
Ranibizumab-EQRN
SUB_CONCEPT->SUBSTANCE
Ranibizumab-EQRN
BIOSIMILAR -> PARENT
Related Record Type Details
RANIBIZUMAB
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:ESTIMATED CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966